

Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand

Authors: Lauren H. Carlton¹, Tiffany Chen¹, Alana L. Whitcombe¹, Reuben McGregor¹, Greg Scheurich², Campbell R. Sheen³, James M. Dickson¹, Chris Bullen¹, Annie Chiang¹, Daniel J. Exeter¹, Janine Paynter¹, Michael G. Baker⁴, Richard Charlewood², Nicole J. Moreland^{1#}

Affiliations:

¹The University of Auckland, Auckland, New Zealand

²The New Zealand Blood Service, Auckland, New Zealand

³Callaghan Innovation, Christchurch, New Zealand

⁴University of Otago, Wellington, New Zealand

#Corresponding Author:

Associate Professor Nicole J. Moreland, Email: n.moreland@auckland.ac.nz

Keywords: SARS-CoV-2, COVID-19, serosurvey, Spike, receptor binding domain, seroprevalence, New Zealand, elimination

18 **Abstract**

19 A large-scale SARS-CoV-2 serosurvey of New Zealand blood donors (n=9806) was
20 conducted at the end of 2020. Seroprevalence, after adjusting for test sensitivity and specificity,
21 was very low (0.1%). This finding is consistent with limited community transmission and provides
22 robust evidence to support New Zealand's successful elimination strategy for COVID-19.

23 Research Letter

24 New Zealand has a strategy of eliminating SARS-CoV-2 that has resulted in a low
 25 incidence of coronavirus-19 disease (COVID-19). The first case was reported on February 26th
 26 2020, and the country entered a strict nationwide lockdown one month later for 49 days (1).
 27 Through rigorous border control and managed isolation and quarantine facilities for new arrivals,
 28 New Zealand has since remained largely COVID-19 free. Globally, serological surveillance has
 29 been utilized throughout the pandemic to define cumulative incidence, including estimations of
 30 missed cases and/or asymptomatic infection. Due to lockdowns and movement restrictions, blood
 31 donors have been used as a sentinel population in many settings (2,3). The aim of this study was
 32 to describe the spread of SARS-CoV-2 in New Zealand via a blood donor serosurvey. Though the
 33 pandemic response has been highly effective, PCR testing was initially restricted due to limited
 34 diagnostic reagents (4) and there have been occasional border incursions and small community
 35 outbreaks, including a cluster in August 2020 with no identified link to the border.

36 Samples were collected by the New Zealand Blood Service via 9 static collection centers
 37 and 36 mobile collection services over a 4-week period (December 3rd 2020 - January 6th 2021)
 38 from individuals aged 16 to 88 years. Duplicates were removed, leaving 9,806 samples for
 39 analysis. Compared with the 2018 New Zealand census, participants were more likely to be aged
 40 40-59 years (43.3% versus 25.9%) and of European ethnicity (77.8% versus 61.0%) but had a
 41 similar proportion of females (49.1% versus 50.7%) and were geographically spread with 16 of 20
 42 district health board regions represented (Table 1 and Appendix). This study was assessed by the
 43 Health and Disability Ethics Committee, and additional consent was not required (21/CEN/21).

Antibodies to the Spike (S) protein and receptor-binding domain (RBD) persist for many months after infection, compared with antibodies to the nucleocapsid (N) protein (5,6), providing rationale for the use of S protein-based assays in serosurveys. The overall serological testing algorithm was optimized for specificity given the low number of reported COVID-19 cases in New Zealand (2,190 as of January 6th 2021) and the associated period prevalence of 0.04%, which limits the positive predictive value of tests with reduced specificity (7). Samples were first screened with a widely used and well-validated 2-step ELISA that comprises a single point dilution assay against the RBD followed by titration against trimeric S protein (Appendix) (8,9). Samples above the cut-off were tested on two further immunoassays – the EuroImmun SARS-CoV-2 IgG ELISA (EuroImmun AG, Lübeck, Germany) and the cPass surrogate Viral Neutralization Test (sVNT) (GenScript, New Jersey, USA) and deemed seropositive if above the cut-off on both commercial assays. Sensitivity and specificity for these assays were determined by Receiver Operator Characteristic (ROC) curves based on previous analyses (413 pre-pandemic negatives, 99 PCR confirmed cases) (Appendix) (9,10).

Of the 9,806 samples, 18 were positive for both Spike IgG (EuroImmun) and antibodies that block the RBD-hACE-2 interaction (sVNT), with the values highly correlated (Pearson r 0.7993, $p < 0.0001$) (Figure). Further analysis of the 18 seropositive samples with a multiplex bead-based assay that detects antibody isotype reactivity to RBD, S and N proteins (5) revealed a pattern consistent with infections that occurred weeks or months prior; a dominance of RBD and S protein IgG with few samples positive for N protein IgG, nor IgA or IgM against any of the three antigens (Figure). Within these 18 seropositive samples, six were retrospectively matched to donors with previously confirmed SARS-CoV-2 infections. That all confirmed cases were detected supports the rationale of the testing algorithm applied. A further four seropositive

samples were from donors with 2020 travel history in settings with a high risk of SARS-CoV-2 exposure (United Kingdom and Europe), suggesting likely infection outside New Zealand. The remaining eight seropositive samples were from seven different district health regions, giving a crude seroprevalence estimate of 0.082% (95% confidence intervals [CI] 0.035-0.16%). Applying the Rogan-Gladen estimate with the Lang-Reiczigel CI method to account for test sensitivity and specificity results in a true seroprevalence estimate of 0.103% (95% CI 0.09-0.12%) (Appendix) and an infection to case ratio of 2.3, based on notified cases on January 6th, 2021, suggesting some undiagnosed infections have occurred. However, this ratio needs to be interpreted with caution given the limitations of the sampling population, together with the extremely low number of seropositive donors, which also precludes any subgroup analysis.

The very low seroprevalence of SARS-CoV-2 infection in New Zealand implies undetected community transmission has been limited. This seroprevalence is broadly similar to a recent study conducted in a low prevalence state of Australia (3), and markedly lower than estimates of >10% from serosurveys in Europe and America where the pandemic has been poorly controlled (<https://serotracker.com>). This study provides the first robust, serological evidence of New Zealand's successful elimination strategy ahead of vaccine roll-out.

Acknowledgments

This work was funded by the School of Medicine Foundation (University of Auckland), and the COVID-19 Innovation Acceleration Fund (Ministry of Business, Innovation and Employment). The 2018 Census data used in this study were supplied by Statistics New Zealand (Stats NZ) and accessed via its Integrated Data Infrastructure (IDI).

Statistics New Zealand Disclaimer

Access to the data used in this study was provided by Stats NZ under conditions designed to give effect to the security and confidentiality provisions of the Statistics Act 1975. The results presented in this study are the work of the author, not Stats NZ or individual data suppliers.

References

1. Baker MG, MBChB NW, Anglemeyer A. Successful Elimination of Covid-19 Transmission in New Zealand. *N Engl J Med*. 2020 Aug 7;1–3.
2. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. *Science*. 2021 Jan 1;371(6524):79–82.
3. Gidding HF, Machalek DA, Hendry A, et al. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney, Australia following the first epidemic wave in 2020. *The Medical Journal of Australia*, *preprint*.
4. Geoghegan JL, Moreland NJ, Gros G, Ussher JE. New Zealand’s science-led response to the SARS-CoV-2 pandemic. *Nat Immunol*. Springer US; 2021 Feb 20;1–2.
5. Whitcombe AL, McGregor R, Craigie A, James A, Charlewood R, Lorenz N, et al. Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. *Clin Transl Immunology*. 2021;10(3):e1261.
6. Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. *Nature reviews Immunology*. 2021 Mar 15;1–12.
7. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, et al. Evaluation of serological tests for SARS-CoV-2: Implications for serology testing in a low-prevalence setting. *J INFECT DIS*. 2020 Aug 6.

- 114 8. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M,
115 et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat
116 Med. 2020 May 12;5:562–12.
- 117 9. McGregor R, Whitcombe AL, Sheen CR, Dickson JM, Day CL, Carlton LH, et al.
118 Collaborative networks enable the rapid establishment of serological assays for
119 SARS-CoV-2 during nationwide lockdown in New Zealand. PeerJ.
120 2020;8(19):e9863.
- 121 10. Craigie A, McGregor R, Whitcombe A, Carlton L, Harte D, Sutherland M, et al.
122 SARS-CoV-2 antibodies in the Southern Region of New Zealand. Pathology -
123 Journal of the RCPA (in press).

124

Table. Demographics of the blood donors, 2018 Census population and COVID-19 cases in New Zealand. The New Zealand blood service donations were collected between the 3rd of December 2020 and the 6th of January 2021. Of the 9,806 individuals, 9,771 are blood donors and 35 are living tissue and stem cell donors. All donors must be free of illness and weigh >50 kg. Notable travel and a history SARS-CoV-2 infection (or contact with a positive case) are recorded prior to collection. Demographics for COVID-19 cases were obtained from the New Zealand Ministry of Health and includes probable and confirmed infections up to and including the 6th of January 2021. The most recent New Zealand census took place in March 2018. Priority ethnicity is reported as defined by the New Zealand Department of Statistics. Abbreviations: MELAA, Middle Eastern, Latin American and African; DHB, District Health Board; MIQ, Managed Isolation and Quarantine.

		Blood Donors		2018 Census Population		COVID-19 cases	
		n	%	n	%	n	%
Total		9,806	100.00%	4,793,361	100.00%	2,190	100.00%
Sex	Male	4,990	50.89%	2,364,315	49.30%	1,037	47.35%
	Female	4,816	49.11%	2,429,046	50.70%	1,153	52.65%
Prioritised Ethnicity	Maori	710	7.24%	777,195	16.20%	192	8.77%
	Pacific Island	192	1.96%	314,202	6.60%	184	8.40%
	Asian	921	9.39%	705,384	14.70%	393	17.95%
	MELAA	144	1.47%	68,283	1.40%	73	3.33%
	European/Other*	7,631	77.82%	2,924,175	61.00%	1,337	61.05%
	Unknown	208	2.12%	4,122	0.10%	11	0.50%
Age	0-14 years	0	0.00%	927,102	19.34%	177	8.08%
	15-19 years⁺	238	2.43%	308,304	6.40%	110	5.02%
	20-29 years	1,754	17.89%	681,963	14.20%	520	23.76%
	30-39 years	1,870	19.07%	624,363	13.00%	398	18.14%
	40-49 years	2,053	20.94%	619,641	12.90%	309	14.12%
	50-59 years	2,196	22.39%	623,445	13.00%	320	14.62%
	60-69 years	1,437	14.65%	510,327	10.60%	222	10.14%
	70+ years	258	2.63%	498,216	10.40%	134	6.12%
DHB	Northland	200	2.04%	179,007	3.70%	28	1.28%
	Auckland	1,478	15.07%	467,595	9.80%	226	10.32%
	Waitemata	613	6.25%	586,329	12.20%	297	13.57%
	Counties	494	5.04%	537,633	11.20%	217	9.91%
	Waikato	1,096	11.18%	405,555	8.50%	194	8.86%
	Taranaki	285	2.91%	117,684	2.50%	16	0.73%
	Lakes	282	2.88%	109,080	2.30%	16	0.73%
	Bay of Plenty	550	5.61%	240,117	5.00%	48	2.19%
	Tairāwhiti	0	0.00%	47,520	1.00%	4	0.18%
	Hawkes Bay	51	0.52%	166,287	3.50%	44	2.01%
	Mid central	792	8.08%	174,993	3.70%	32	1.46%
	Whanganui	0	0.00%	64,599	1.30%	9	0.41%
	Wairarapa	51	0.52%	45,327	0.90%	8	0.37%
	Hutt Valley	214	2.18%	148,509	3.10%	24	1.10%
	Capital and Coast	1,082	11.03%	303,957	6.30%	96	4.39%
	Nelson Marlborough	0	0.00%	150,528	3.10%	49	2.24%
	West Coast	0	0.00%	31,578	0.70%	5	0.23%
	Canterbury	1,774	18.09%	539,628	11.30%	168	7.67%
	South Canterbury	113	1.15%	58,977	1.20%	17	0.78%
	Southern	731	7.45%	324,387	6.80%	216	9.87%
	Unknown	0	0.00%	94,071	2.00%	0	0.00%
MIQ	-	0	0.00%	0	0.00%	476	21.70%

* 'Other' comprises of n=28 (0.20%) of the blood donor population, and n= 51,447 (1.10%) of the New Zealand census population.

⁺ All blood donors are at least 16 years of age.

Figure. Antibody characteristics of the seropositive donors (n=18). (a) Seropositivity was confirmed by EuroImmun S1 IgG (top) and the surrogate Viral Neutralization Test (sVNT, bottom). Six donors had PCR confirmed SARS-CoV-2 infection (dark grey), four had relevant travel history (dark turquoise), and eight were identified in this study (orange). The manufacturers cut-offs are shown (black dotted line). (b) Pearson correlation of sVNT and the Euroimmun IgG ELISA (n=18). (c) Rose plot showing percentage of seropositive donors over baseline for IgG, IgA and IgM antibodies against the RBD, Spike (S) and Nucleocapsid (N) proteins determine using a multi-plex Luminex bead assay.

